Central Precocious Puberty clinical trials at UCSF

1 in progress, 0 open to eligible people

Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)
Sorry, in progress, not accepting new patients
The primary objective of this study is to evaluate the efficacy of Debio 4326 in suppressing serum luteinizing hormone (LH) to prepubertal levels 52 weeks after the first Debio 4326 injection in pediatric participants with central precocious puberty (CPP).
San Francisco, California and other locations

Last updated: November 28, 2025